RAPT Therapeutics (NASDAQ:RAPT)’s share price was up 10.3% during mid-day trading on Wednesday after UBS Group raised their price target on the stock from $26.00 to $31.00. UBS Group currently has a buy rating on the stock. RAPT Therapeutics traded as high as $31.46 and last traded at $27.53, approximately 205,100 shares traded hands during trading. An increase of 95% from the average daily volume of 105,237 shares. The stock had previously closed at $24.95.
Several other equities research analysts have also recently issued reports on RAPT. BMO Capital Markets started coverage on shares of RAPT Therapeutics in a research note on Monday, November 25th. They set an “outperform” rating and a $35.00 price target on the stock. Wells Fargo & Co started coverage on shares of RAPT Therapeutics in a research note on Monday, November 25th. They set an “outperform” rating and a $33.00 price target on the stock.
In other news, major shareholder Group Ii Lp Column purchased 625,000 shares of the firm’s stock in a transaction on Monday, November 4th. The shares were bought at an average cost of $14.49 per share, with a total value of $9,056,250.00. Also, CEO Brian Russell Wong bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The stock was bought at an average cost of $14.49 per share, for a total transaction of $362,250.00. Insiders have acquired a total of 651,600 shares of company stock worth $9,441,684 over the last ninety days.
RAPT Therapeutics, Inc, a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases.
Further Reading: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.